Last edition
News about "small molecule therapies "
Brenig Therapeutics Initiates First-in-Human Study of BT-409, Advances BT-267 Parkinson's Programme
Brenig Therapeutics has launched a first-in-human Phase I study of BT-409, a brain-selective NLRP3 inhibitor, while advancing BT-267 toward Phase 1b and Phase II studies in Parkinson’s disease.
Small-molecule Therapies | 20/01/2026 | By News Bureau | 226
Skyhawk Therapeutics Inaugurates its State-of-the-Art Labs in Switzerland
Skyhawk Therapeutics, Inc. has expanded its facilities with its new state-of-the-art labs in Superlab Suisse, in Basel Switzerland.
Small Molecule Therapies | 26/06/2024 | By Aishwarya | 972
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy